Navidea Biopharmaceuticals, Inc.
NAVB
$0.0001
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -98.81% | -92.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -98.81% | -92.22% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -198.21% | -231.64% |
| SG&A Expenses | 25.47% | 5.23% | -34.49% | -43.74% | -29.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.63% | -18.54% | -17.38% | -12.08% | -6.35% |
| Operating Income | 9.34% | 16.93% | 17.38% | 10.88% | 2.93% |
| Income Before Tax | 60.49% | 53.55% | 50.58% | 4.64% | -135.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 60.49% | 53.55% | 50.58% | 4.64% | -134.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.49% | 301.09% | 50.58% | 4.64% | -134.14% |
| EBIT | 9.34% | 16.93% | 17.38% | 10.88% | 2.93% |
| EBITDA | 9.54% | 17.24% | 17.68% | 11.09% | 3.23% |
| EPS Basic | 90.99% | 221.80% | 54.30% | 11.15% | -211.50% |
| Normalized Basic EPS | 72.06% | 42.81% | 53.62% | 29.46% | 0.20% |
| EPS Diluted | 90.99% | 221.80% | 54.30% | 11.15% | -211.50% |
| Normalized Diluted EPS | 72.06% | 42.81% | 53.62% | 29.46% | 0.20% |
| Average Basic Shares Outstanding | 223.32% | 59.38% | 8.10% | 7.34% | 2.02% |
| Average Diluted Shares Outstanding | 223.32% | 59.38% | 8.10% | 7.34% | 2.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
